In recent years, liquid biopsy has garnered the attention of numerous individuals. This may not be a surprise, as the potential for clinical implications could result from the ability to detect and characterize malignancies in a modest and repeatable manner. It is no surprise that extraordinary devices have been created to accomplish this task.
Despite this, clinical oncologists have not yet adopted the technique as a standard tool. The research community appears to be losing focus on a variety of assays that are based on different principles, as there are so many things to focus on.
Unfortunately, the two biomarkers detected by liquid biopsy, Circulating Tumor Cells (CTCs) and Circulating cell-free tumor DNA (ctDNA), are still susceptible to technical variability. This is primarily the case for pre-analytical and analytical steps.
Fortunately, initiatives are already being made to resolve these concerns, making sure that more clinicians around the world have access to liquid biopsy. Nevertheless, this does not imply that their primary objective is to select and refine a singular liquid biopsy approach.
The primary focus is on identifying the precise combination of indicators that indicate the status of a specific health complication, whether it be lung cancer or any other type, as well as its origin and progression. We also need to keep a close watch on the immune cells of the circulating microenvironment, so the situation does not conclude there.
More interventional clinical trials are required to make liquid biopsies successful because researchers have known about their capabilities for some time now. However, how is this feasible without surrendering any of one’s principles?
Well, that is where policymakers in the industry must intervene. By doing so, it will be simple and easy to implement sophisticated methods, making it a non-invasive, quick, and dependable decision-making tool that we can rely on at any time.
The future of liquid biopsy lung cancer appears to be promising as additional advancements are implemented. What is even more intriguing is the fact that clinicians in various regions of the world are highly aware of liquid biopsy.
You need to know what is going on if you want to avoid being left behind. Fortunately, this is no longer a concern once you have a comprehensive understanding of lung cancer and the proper methods for diagnosis and treatment.
